Crispr Therapeutics AG (CRSP)
Healthcare
Biotechnology
49.60 $
+3.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Crispr Therapeutics AG (CRSP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.5% of the shares are freely tradable; institutional investors hold 79.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
79.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
23.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
99Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Investment Management LLC | 11.49 | 11,313,623 | +7.5 | 03/31/2026 |
| BlackRock Inc | 7.80 | 7,680,073 | +2.3 | 03/31/2026 |
| Orbis Allan Gray Ltd | 6.20 | 6,106,011 | +2.6 | 03/31/2026 |
| Capital World Investors | 4.80 | 4,725,037 | +0.0 | 03/31/2026 |
| State Street Corp | 4.04 | 3,982,500 | +6.1 | 03/31/2026 |
| GSK PLC | 3.27 | 3,220,627 | +0.0 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 3.00 | 2,952,595 | -41.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Disruptive Innovation Full Composite | 5.92 | 5,833,283 | -20.4 | 06/30/2026 |
| ARK Innovation ETF | 5.81 | 5,721,590 | -0.1 | 07/28/2026 |
| iShares Russell 2000 ETF | 2.44 | 2,400,964 | +1.1 | 07/28/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.